폐경 후 골다공증 치료 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Postmenopausal Osteoporosis Treatment Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 15.41 Billion in 2025 to USD 24.85 Billion by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).

The global postmenopausal osteoporosis treatment market is driven by the increasing aging female population and the associated bone loss due to estrogen deficiency. This market's significance is highlighted by the high incidence of fragility fractures, which lead to notable morbidity, mortality, and healthcare costs, prompting payers and policymakers to emphasize early diagnosis and effective treatment. The landscape has shifted from traditional oral bisphosphonates to advanced biologics, enhancing patient outcomes and adherence due to fewer side effects. The integration of AI is revolutionizing diagnosis and treatment personalization, leveraging image analysis and predictive modeling to identify risks and tailor therapies. This, combined with improved screening efforts and the availability of novel therapies, is expanding access and driving demand in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Postmenopausal Osteoporosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Postmenopausal Osteoporosis Treatment Market Segments Analysis

Global postmenopausal osteoporosis treatment market is segmented by drug class, route, distribution and region. Based on drug class, the market is segmented into Bisphosphonates, Denosumab (RANK Ligand Inhibitor), Teriparatide/PTH Analogs, SERMs (Selective Estrogen Receptor Modulators) and Romosozumab. Based on route, the market is segmented into Oral, Injectable and Intravenous. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Postmenopausal Osteoporosis Treatment Market

The rise in public and clinical awareness regarding postmenopausal osteoporosis significantly contributes to early diagnosis and proactive management, resulting in a larger patient base seeking treatment. Enhanced educational initiatives and training for healthcare providers lead to improved identification of risk factors and an understanding of treatment benefits, which promotes prompt initiation and adherence to therapeutic regimens. As awareness increases, patients tend to engage more in shared decision-making with their healthcare professionals and actively explore various treatment options. This heightened engagement not only drives sustained demand for both pharmacological and supportive care but also encourages investment in service delivery and product innovation.

Restraints in the Global Postmenopausal Osteoporosis Treatment Market

The Global Postmenopausal Osteoporosis Treatment market faces significant challenges due to high treatment costs and inconsistent reimbursement policies, which impede patient access and discourage both the initiation and continuation of prescribed therapies, ultimately hindering market expansion. Elevated out-of-pocket expenses often compel patients and healthcare providers to opt for more affordable or non-pharmacological management options, even when clinically indicated, leading to a decrease in prescription volumes. Additionally, payer limitations and prior authorization processes create complexities in prescribing, causing delays in therapy commencement that negatively affect treatment adherence and perceived value. These economic and systemic barriers dampen demand, slow the adoption of innovative therapies, and diminish incentives for market growth and service development.

Market Trends of the Global Postmenopausal Osteoporosis Treatment Market

The Global Postmenopausal Osteoporosis Treatment market is increasingly embracing personalized care pathways, which focus on customizing prevention and treatment strategies based on individual patient profiles. By incorporating genetic risks, assessments of bone quality, existing comorbidities, and lifestyle factors, healthcare providers are able to select the most effective therapies and monitoring protocols. The use of decision-support tools and enhanced interdisciplinary collaboration is becoming standard practice, optimizing both treatment efficacy and duration. This trend fosters improved patient adherence and health outcomes, while prompting ongoing refinements in clinical guidelines and encouraging payer recognition of evidence-based reimbursement practices.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Postmenopausal Osteoporosis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Bisphosphonates
• Denosumab (RANK Ligand Inhibitor)
• Teriparatide/PTH Analogs
• SERMs (Selective Estrogen Receptor Modulators)
• Romosozumab

Global Postmenopausal Osteoporosis Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Intravenous

Global Postmenopausal Osteoporosis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Postmenopausal Osteoporosis Treatment Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Postmenopausal Osteoporosis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Route, Distribution, Region)
  • US
  • Canada
• Europe (Drug Class, Route, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (Prolia/Evenity)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Forteo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA (Evenity - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radius Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Warner Chilcott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Takeda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations